We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 15, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , The Coca-Cola Co. (KO - Free Report) , Adobe Inc. (ADBE - Free Report) , SAP SE (SAP - Free Report) and GlaxoSmithKline plc (GSK - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Pfizer, Coca-Cola and Adobe
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc., The Coca-Cola Co., and Adobe Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Pfizer have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+42.0% vs. +18.5%). Pfizer boasts a diversified portfolio of innovative drugs and vaccines including Ibrance and Prevnar. The Zacks analyst believes that no company is as strongly placed in the COVID vaccines/treatment market as Pfizer right now. Its COVID-19 vaccine has become a key contributor to the top line. The vaccine together with Pfizer's promising oral antiviral pill for COVID-19, Paxlovid is expected to generate a combined $54 billion in sales in 2022.
Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth. However, currency headwinds and pricing pressure are key top-line headwinds. Concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure.
Shares of Coca-Cola have outperformed the Zacks Beverages - Soft drinks industry over the past year (+13.5% vs. +7.9%). Coca-Cola's top and bottom-line surpassed estimates for the fourth straight quarter. The Zacks analyst believes that the results benefited from the company's strategic transformation and ongoing recovery around the world.
Revenues gained from the investments and ongoing recovery in markets, where the pandemic-led disruptions are subsiding. Strength across majority of the markets, investments in marketplace, recovery in certain markets as well as the cycling of last year's pandemic-led impacts aided volumes.
The company provided an upbeat 2022 view. It is poised to gain from innovations and accelerating digital investments. However, pressures from higher supply chain costs, including transportation and input costs remain. Higher marketing spends are also concerning.
Shares of Adobe have underperformed the Zacks Computer – Software industry over the past year (-7.0% vs. +9.7%). The Zacks analyst believes that lower end-market demand and high acquisition expenses remain major overhangs for the company.
However, Adobe is benefiting from strong demand for its cloud products. The company's Creative Cloud, Document Cloud and Adobe Experience Cloud products are helping it drive top-line growth. Additionally, rising subscription revenues and solid momentum across the mobile apps remain major positives.
Further, growth in emerging markets, robust online video creation demand, strong Acrobat adoption and improving average revenue per user remain tailwinds. The Zacks analyst remain optimistic about Adobe's market position, compelling product lines, persistent innovation and solid adoption of Creative Cloud and Adobe marketing cloud.
Other noteworthy reports we are featuring today include SAP SE and GlaxoSmithKline plc.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline
For Immediate Release
Chicago, IL – March 15, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , The Coca-Cola Co. (KO - Free Report) , Adobe Inc. (ADBE - Free Report) , SAP SE (SAP - Free Report) and GlaxoSmithKline plc (GSK - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Pfizer, Coca-Cola and Adobe
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc., The Coca-Cola Co., and Adobe Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Pfizer have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+42.0% vs. +18.5%). Pfizer boasts a diversified portfolio of innovative drugs and vaccines including Ibrance and Prevnar. The Zacks analyst believes that no company is as strongly placed in the COVID vaccines/treatment market as Pfizer right now. Its COVID-19 vaccine has become a key contributor to the top line. The vaccine together with Pfizer's promising oral antiviral pill for COVID-19, Paxlovid is expected to generate a combined $54 billion in sales in 2022.
Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth. However, currency headwinds and pricing pressure are key top-line headwinds. Concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure.
(You can read the full research report on Pfizer here >>>)
Shares of Coca-Cola have outperformed the Zacks Beverages - Soft drinks industry over the past year (+13.5% vs. +7.9%). Coca-Cola's top and bottom-line surpassed estimates for the fourth straight quarter. The Zacks analyst believes that the results benefited from the company's strategic transformation and ongoing recovery around the world.
Revenues gained from the investments and ongoing recovery in markets, where the pandemic-led disruptions are subsiding. Strength across majority of the markets, investments in marketplace, recovery in certain markets as well as the cycling of last year's pandemic-led impacts aided volumes.
The company provided an upbeat 2022 view. It is poised to gain from innovations and accelerating digital investments. However, pressures from higher supply chain costs, including transportation and input costs remain. Higher marketing spends are also concerning.
(You can read the full research report on Coca-Cola here >>>)
Shares of Adobe have underperformed the Zacks Computer – Software industry over the past year (-7.0% vs. +9.7%). The Zacks analyst believes that lower end-market demand and high acquisition expenses remain major overhangs for the company.
However, Adobe is benefiting from strong demand for its cloud products. The company's Creative Cloud, Document Cloud and Adobe Experience Cloud products are helping it drive top-line growth. Additionally, rising subscription revenues and solid momentum across the mobile apps remain major positives.
Further, growth in emerging markets, robust online video creation demand, strong Acrobat adoption and improving average revenue per user remain tailwinds. The Zacks analyst remain optimistic about Adobe's market position, compelling product lines, persistent innovation and solid adoption of Creative Cloud and Adobe marketing cloud.
(You can read the full research report on Adobe here >>>)
Other noteworthy reports we are featuring today include SAP SE and GlaxoSmithKline plc.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.